Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157110 | 0.88 | RAB9A (0.53) | GAAKMT2AMEN1NR1I2SMN1; SMN2 | |
| SCHEMBL115661 | 0.85 | GAA (0.60) | GAAMAPK1KMT2AMEN1HTT | |
| SCHEMBL29991362 | 0.85 | GAA (0.60) | GAAMAPK1KMT2AMEN1HTT | |
| SCHEMBL24150515 | 0.85 | NR1I2 (0.43) | P2RX7KMT2AMEN1LMNAHTT | |
| SCHEMBL4568026 | 0.84 | MAPT (0.48) | GAAKMT2AMEN1LMNAHTT | |
| SCHEMBL4568018 | 0.84 | NLRP3 (0.55) | GAALMNAPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL1007579 | 0.84 | KMT2A (0.45) | GAAMAPK1KMT2AMEN1HTT | |
| SCHEMBL5565178 | 0.84 | HDAC2 (0.47) | GAAKMT2AMEN1MAPTPOLB | |
| SCHEMBL14598625 | 0.84 | TDP1 (0.51) | P2RX7KMT2AMEN1LMNAMAPT | |
| SCHEMBL31515782 | 0.84 | KMT2A (0.45) | GAAMAPK1KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| EP-1515975-B1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER (US) | 2007-09-19 | — | — | EP | disclosed |
| US-7045528-B2 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060079548-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | disclosed |
| US-6869962-B2 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| EP-0772592-B1 | 1H-INDOLE-1-FUNCTIONAL sPLA 2 INHIBITORS | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6252084-B1 | THERAPY FOR SEPSIS SHOCK | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0620215-B1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | LILLY CO ELI (US) | 1999-08-18 | — | — | EP | disclosed |
| EP-0772592-A4 | 1H-INDOLE-1-FUNCTIONAL sPLA 2? INHIBITORS | LILLY CO ELI (US) | 1998-07-08 | — | — | EP | disclosed |
| US-5684034-A | INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE | ELI LILLY AND COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| US-5641800-A | ALLEVIATE EFFECT OF SEPTIC SHOCK, ADULT RESPIRATORY DISTRESS SYNDROME, PANCREATITIS, TRAUMA, BRONCHIAL ASTHMA, ALLERGIC RHINITIS, AND RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0772592-A1 | 1H-INDOLE-1-FUNCTIONAL sPLA 2? INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003376-A1 | 1H-INDOLE-1-FUNCTIONAL sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | GAA 4525/4885MAPK1 855/4885P2RX7 694/4885 |
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | GAA 780/4885MAPK1 3732/4885P2RX7 530/4885 |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | GAA 780/4885MAPK1 3732/4885P2RX7 530/4885 |
| US-20060079548-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | TPD52L2, DPYD, CCND2 | GAA 853/4885MAPK1 3901/4885P2RX7 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.